Which is more profitable, Johnson & Johnson or Merck KGaA?

Johnson & Johnson keeps more of every sale as profit.

Which grows faster, Johnson & Johnson or Merck KGaA?

Johnson & Johnson grew its sales faster in recent years.

Which is cheaper, Johnson & Johnson or Merck KGaA?

Merck KGaA costs less for each unit of yearly profit (lower P/E).

Which has less debt, Johnson & Johnson or Merck KGaA?

Johnson & Johnson would need fewer years of earnings to pay off its debt.

Johnson & JohnsonJNJvs

Merck KGaAMRK.DE

Johnson & Johnson vs Merck KGaA stock

Side by side in plain words: who keeps more of its sales, grows faster, costs less and owes less.

In one sentence

Johnson & Johnson is more profitable, grows faster and has less debt. Merck KGaA is cheaper for its profits.

Side by side

	Johnson & Johnson	Merck KGaA
	$688 billion	€65.0 billion
	28.5%	12.4%
	+2.7%	−1.7%
	25.7×	24.9×
	0.7 years	1.6 years
	21.0%	6.4%
	2.3%	0.4%

Open Johnson & Johnson Open Merck KGaA

How we compare

Four contests with the same rules as each stock page: profit kept from sales (higher wins), yearly sales growth across the last reports, up to five years (higher wins), price per unit of yearly profit (lower P/E wins; a company without profit loses) and debt in years of earnings (lower wins). A winner is only named when both companies have the number.

More comparisons: Johnson & Johnson vs Moderna · Johnson & Johnson vs Novo Nordisk · Johnson & Johnson vs Novartis · Johnson & Johnson vs Pfizer · Merck KGaA vs Eli Lilly · Merck KGaA vs Merck & · Merck KGaA vs Roche · Merck KGaA vs AbbVie